Pipeline

Greenstone is advancing two promising compounds toward Investigational New Drug (IND) application. With a commitment to addressing unmet medical needs, we leverage cutting-edge science and a team of experts to translate innovative research into potential treatments that aim to improve patient outcomes.

Product

Indication

Discovery

Preclinical

IND-Enabling

Phase 1

Phase 2

Phase 3

GSB-D100

Fibrosis

58%

GSB-D300

Inflammatory

58%

Product

Indication

Discovery

Preclinical

IND-Enabling

Phase 1

Phase 2

GSB-D100

Fibrosis

58%

GSB-D300

Inflammatory

58%

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id

Progress Bar
80%
Web Designer